Patents Assigned to Dong-A ST Co., Ltd.
-
Patent number: 11840574Abstract: The present invention relates to an antibody that specifically binds to death receptor 5 (DR5) and has a function of killing cancer cells. Specifically, provided are an anti-DR5 antibody or antigen-binding fragment thereof, and a use of the antibody or antigen-binding fragment for preventing or treating cancer. The present invention is characterized in that the anti-DR5 antibody or antigen-binding fragment thereof is improved in terms of affinity to DR5, stability, and an effect of killing cancer cells.Type: GrantFiled: February 8, 2018Date of Patent: December 12, 2023Assignee: DONG-A ST CO., LTD.Inventors: Hyounmie Doh, Dongsop Lee, Hanyoung Lee, Yoojin Kim, Kyungmi Han, Eunee Jung, Donghyeon Kim, Eongsup Song, Kum-Joo Shin, Soyon Woo
-
Patent number: 11713344Abstract: A novel peptide analog of acylated oxyntomodulin and its uses are disclosed. A pharmaceutical composition containing the novel peptide analog is useful and effective for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptide analog and a composition containing the peptide analog are superior to those of wild-type oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition containing the peptide analog is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.Type: GrantFiled: August 24, 2021Date of Patent: August 1, 2023Assignee: DONG-A ST CO., LTD.Inventors: Jae-Sung Yang, Kyung-Seok Lee, Yu-Na Chae, Gye-Rim Baek, Tae-Hyoung Kim, Ill-Hun Jung, Chae-Lim Ryu, Weon-Bin Im
-
Publication number: 20230220035Abstract: A novel long-acting acylated oxyntomodulin peptide analogue having dual agonism on GLP-1 and glucagon receptors (dual GLP-1R/GlucagonR agonism) and a pharmaceutical composition including the same are disclosed. The novel long-acting acylated oxyntomodulin peptide analogue and the composition are useful for the prevention and treatment of obesity and overweight, or non-insulin-dependent diabetes accompanied by obesity and overweight. The acylated oxyntomodulin peptide analog has dual agonism for GLP-1/glucagon receptors and has an excellent increased in vivo half-life, and the pharmaceutical composition containing the same is useful for the treatment of metabolic diseases such as obesity and diabetes.Type: ApplicationFiled: April 15, 2021Publication date: July 13, 2023Applicant: DONG-A ST CO., LTD.Inventors: Jae-Sung YANG, Kyung-Seok LEE, Yu-Na CHAE, Tae-Hyoung KIM, Ill-Hun JUNG, Chae-Lim RYU, Dae-Young LEE
-
Publication number: 20230201131Abstract: A percutaneous absorption preparation for the treatment of dementia wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient and a stabilizer that is either (i) a mixture of a thiocyanate salt and a compound selected from the group consisting of tea catechin, (+)-catechin, epigallocatechin gallate, ascorbic acid, and isoascorbic acid, or (ii) a mixture of monothioglycerol and a compound selected from the group consisting of tea catechin, (+)-catechin, epigallocatechin gallate, and ascorbic acid is disclosed. The percutaneous absorption preparation meets the criteria of Procedure 1 and Procedure 2 of the U.S. Pharmacopoeia in short-term stress test (70° C. 48 hours storage), long-term accelerated test 1 (40° C. relative humidity 75% 1 month storage), and long-term accelerated test 2 (40° C. relative humidity 75% 3 months storage), and exhibits improved stability for long-term preservation.Type: ApplicationFiled: May 12, 2021Publication date: June 29, 2023Applicants: DONG-A ST CO., LTD., KM TRANSDERM LTD.Inventors: Sun-Woo JANG, Chang-Yell SHIN, Hae-Sun KIM, Kwang-Ho CHA, Hyun-jung KIM, Sang-Min HYUN, Masaoki GOTO
-
Publication number: 20220119473Abstract: A novel peptide analog of acylated oxyntomodulin and its uses are disclosed. A pharmaceutical composition containing the novel peptide analog is useful and effective for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptide analog and a composition containing the peptide analog are superior to those of wild-type oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition containing the peptide analog is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.Type: ApplicationFiled: August 24, 2021Publication date: April 21, 2022Applicant: DONG-A ST CO., LTD.Inventors: Jae-Sung YANG, Kyung-Seok LEE, Yu-Na CHAE, Gye-Rim BAEK, Tae-Hyoung KIM, Ill-Hun JUNG, Chae-Lim RYU, Weon-Bin IM
-
Publication number: 20220047524Abstract: A percutaneous absorption preparation including donepezil for the treatment of dementia is disclosed. The percutaneous absorption preparation for the treatment of dementia includes a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; monothioglycerol, thiocyanate metal salt (preferably potassium salt) or dimethylthiourea as a stabilizer; and a pressure-sensitive adhesive. Also disclosed is a percutaneous absorption preparation for the treatment of dementia with reduced the formation of donepezil impurities.Type: ApplicationFiled: September 5, 2019Publication date: February 17, 2022Applicants: DONG-A ST CO., LTD, KM TRANSDERM LTD.Inventors: Sun-Woo JANG, Chang-Yell SHIN, Hae-Sun KIM, Kwang-Ho CHA, Hyun-Jung KIM, Masaoki GOTO
-
Patent number: 11236142Abstract: The present invention relates to a novel peptide analog of acylated oxyntomodulin and a pharmaceutical composition comprising the same for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptides are superior to those of natural oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition comprising said peptides is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.Type: GrantFiled: August 16, 2018Date of Patent: February 1, 2022Assignee: DONG-A ST CO., LTD.Inventors: Jae-Sung Yang, Kyung-Seok Lee, Yu-Na Chae, Gye-Rim Baek, Tae-Hyoung Kim, Ill-Hun Jung, Chae-Lim Ryu, Weon-Bin Im
-
Publication number: 20210113648Abstract: Disclosed are a pharmaceutical composition and a health functional food for the prevention and treatment of diabetic peripheral neuropathy, comprising an herb extract of a mixture of 3.5:1 Dioscorea Rhizoma:Dioscorea nipponica (w/w). Having the ability to synergistically increase in vivo levels of nerve growth factor, compared to the extracts from the herbs alone or herb mixtures of other weight ratios, the mixed herb extract is effective for preventing the apoptosis of nerve cells and promoting nerve regeneration. Thus, it can be applied to pharmaceutical compositions and health functional foods preventive and curative of diabetic peripheral neuropathy.Type: ApplicationFiled: September 30, 2020Publication date: April 22, 2021Applicant: DONG-A ST CO., LTD.Inventors: Soon-Hoe KIM, Mi-Won SON, Sang-Zin CHOI, Hye-Ju KIM, Ja-Young RYU, Sun-Yeou KIM
-
Publication number: 20210059956Abstract: A percutaneous absorption preparation is disclosed. The percutaneous absorption preparation contains donepezil for treatment of dementia, wherein the preparation includes: (a) donepezil or its pharmaceutically acceptable salt as active component, (b) propylene glycol monocaprylate as solubilizer, and (c) styrene-isoprene-styrene block copolymer (“SIS”) as adhesive. The percutaneous absorption preparation has low skin irritation and high skin penetration.Type: ApplicationFiled: November 7, 2018Publication date: March 4, 2021Applicants: DONG-A ST CO., LTD., KM TRANSDERM LTD.Inventors: Sun-Woo JANG, Chang-Yell SHIN, Jeong-Soo KIM, Hae-Sun KIM, Kwang-Ho CHA, Hyun-Jung KIM, Masaoki GOTO
-
Patent number: 10894768Abstract: The present invention relates to a novel salt of (R)-(1-methylpyrrolidine-3-yl)methyl(3?-chloro-4?-fluoro-[1,1?-biphenyl]-2-yl)carbamate and a crystal form thereof. Also, the novel salt of (R)-(1-methylpyrrolidine-3-yl)methyl(3?-chloro-4?-fluoro-[1,1?-biphenyl]-2-yl)carbamate and the crystal form thereof according to examples of the present invention have remarkably excellent stability, hygroscopicity and solubility.Type: GrantFiled: August 26, 2016Date of Patent: January 19, 2021Assignee: Dong-A St Co., Ltd.Inventors: Woo Young Kwak, Chang-Yong Shin, Punna Reddy Ullapu, Sun-Ho Choi, Min-Jung Lee, Ji-Su Kim
-
Publication number: 20200397845Abstract: This invention relates to a pharmaceutical composition and a health functional food for preventing or improving neurodegenerative disorders comprising mixed herb extracts of Dioscorea Rhizoma and Dioscorea nipponica in a weight ratio of 3.5:1 (w/w). The herb extracts mixed Dioscorea Rhizoma and Dioscorea nipponica in a weight ratio of 3.5:1 have the synergetic effects on increasing the amount of nerve growth factor in vivo, increasing the neural cell proliferation, promoting the formation of neuritis and enhancing cognitive abilities. Thus, the herb extracts of the present invention may be used for a pharmaceutical composition and a health functional food for preventing or treating neurodegenerative disorders.Type: ApplicationFiled: June 4, 2020Publication date: December 24, 2020Applicant: DONG-A-ST Co., Ltd.Inventors: Soon Hoe KIM, Mi-Won SON, Sang-Zin CHOI, Hye-Ju KIM, Ja-Young RYU, Sun-Yeou KIM
-
Publication number: 20200354425Abstract: The present invention relates to a novel peptide analog of acylated oxyntomodulin and a pharmaceutical composition comprising the same for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptides are superior to those of natural oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition comprising said peptides is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.Type: ApplicationFiled: August 16, 2018Publication date: November 12, 2020Applicant: DONG-A ST CO., LTD.Inventors: Jae-Sung YANG, Kyung-Seok LEE, Yu-Na CHAE, Gye-Rim BAEK, Tae-Hyoung KIM, Ill-Hun JUNG, Chae-Lim RYU, Weon-Bin IM
-
Patent number: 10813973Abstract: Disclosed are a pharmaceutical composition and a health functional food for the prevention and treatment of diabetic peripheral neuropathy, comprising an herb extract of a mixture of 3.5:1 Dioscorea Rhizoma:Dioscorea nipponica (w/w). Having the ability to synergistically increase in vivo levels of nerve growth factor, compared to the extracts from the herbs alone or herb mixtures of other weight ratios, the mixed herb extract is effective for preventing the apoptosis of nerve cells and promoting nerve regeneration. Thus, it can be applied to pharmaceutical compositions and health functional foods preventive and curative of diabetic peripheral neuropathy.Type: GrantFiled: April 10, 2017Date of Patent: October 27, 2020Assignee: DONG-A ST CO., LTD.Inventors: Soon-Hoe Kim, Mi-Won Son, Sang-Zin Choi, Hye-Ju Kim, Ja-Young Ryu, Sun-Yeou Kim
-
Patent number: 10709752Abstract: This invention relates to a pharmaceutical composition and a health functional food for preventing or improving neurodegenerative disorders comprising mixed herb extracts of Dioscorea Rhizoma and Dioscorea nipponica in a weight ratio of 3.5:1 (w/w). The herb extracts mixed Dioscorea Rhizoma and Dioscorea nipponica in a weight ratio of 3.5:1 have the synergetic effects on increasing the amount of nerve growth factor in vivo, increasing the neural cell proliferation, promoting the formation of neuritis and enhancing cognitive abilities. Thus, the herb extracts of the present invention may be used for a pharmaceutical composition and a health functional food for preventing or treating neurodegenerative disorders.Type: GrantFiled: April 10, 2017Date of Patent: July 14, 2020Assignee: DONG-A ST CO., LTD.Inventors: Soon-Hoe Kim, Mi-Won Son, Sang-Zin Choi, Hye-Ju Kim, Ja-Young Ryu, Sun-Yeou Kim
-
Patent number: 10660928Abstract: The present invention relates to a pharmaceutical composition for treating and preventing degenerative neurological disorders, containing, as an active ingredient, a mixture extract of two or more types selected from the group consisting of Moutan Root Bark, Angelica Dahurica Root, and Bupleurum Root, or a fraction thereof.Type: GrantFiled: March 8, 2017Date of Patent: May 26, 2020Assignees: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY, DONG-A ST CO., LTD.Inventors: Youngmi Kim, Myung Sook Oh, Seon-Pyo Hong, Mi Won Sohn, Jin Seok Jeong, Hai Hua Jiang, Eunjin Kim, Ja Young Ryu, Young Woong Cho, Xiao Fei Du, Sang Zin Choi, Jeong Soo Kim, Byoung Moon Kim
-
Patent number: 10428055Abstract: The present invention relates to a substituted piperidines represented by following Chemical Formula 1, which have a GPR119 agonistic activity, a method for preparing the same, and a pharmaceutical composition including the same: wherein A, B, and X are defined therein.Type: GrantFiled: July 24, 2015Date of Patent: October 1, 2019Assignee: DONG-A ST CO., LTD.Inventors: Jae Sung Yang, Gye Rim Baek, Yoon Jung Kim, Chi Young Ahn, Jae Young Lee, Il Hoon Jung, Mi Kyung Kim, So Mi Kang, Hyo Ju Lee, Yu Na Chae, Ye Hwang Cheong, Tae Hyoung Kim, Eun Kyoung Yang, Moon Ho Son, Chang Yell Shin
-
Patent number: 10398747Abstract: Disclosed are a pharmaceutical composition and a health functional food for the prevention and treatment of diabetic peripheral neuropathy, comprising an herb extract of a mixture of 3.5:1 Dioscorea Rhizoma:Dioscorea nipponica (w/w). Having the ability to synergistically increase in vivo levels of nerve growth factor, compared to the extracts from the herbs alone or her mixtures of other weight ratios, the mixed herb extract is effective for preventing the apoptosis of nerve cells and promoting nerve regeneration. Thus, it can be applied to pharmaceutical compositions and health function foods preventive and curative of diabetic peripheral neuropathy.Type: GrantFiled: July 12, 2018Date of Patent: September 3, 2019Assignee: Dong-A St Co., Ltd.Inventors: Soon-Hoe Kim, Mi-Won Son, Sang-Zin Choi, Hye-Ju Kim, Ja-Young Ryu, Sun-Yeou Kim
-
Publication number: 20190092763Abstract: The present invention relates to a novel compound having a GPR119 agonistic activity, a method for preparing the same, and a pharmaceutical composition including the same as an effective component. The present invention has an effective hypoglycemic action and an effect on pancreatic beta cells, and also improves lipid metabolism which is a chronic cardiovascular risk factor, thereby having a treatment and/or prevention effect of a metabolic disease such as diabetes.Type: ApplicationFiled: July 24, 2015Publication date: March 28, 2019Applicant: DONG-A ST CO., LTD.Inventors: Jae Sung Yang, Gye Rim Baek, Yoon Jung Kim, Chi Young Ahn, Jae Young Lee, Il Hoon Jung, Mi Kyung Kim, So Mi Kang, Hyo Ju Lee, Yu Na Chae, Ye Hwang Cheong, Tae Hyoung Kim, Eun Kyoung Yang, Moon Ho Son, Chang Yell Shin
-
Patent number: 10159667Abstract: The present invention relates to a composition for preventing or treating renal diseases. The composition of the present invention improves lipid metabolism, prevents histological damage including renal fibrosis, alleviates microalbuminuria, and maintains nephrons of renal glomeruli. Therefore, the composition is useful for treating renal diseases.Type: GrantFiled: June 17, 2014Date of Patent: December 25, 2018Assignee: DONG-A ST Co., LtdInventors: Dae Ryong Cha, Young Sun Kang, Jin Joo Cha, Ji Eun Lee, Hyun Wook Kim, Mi Hwa Lee, Jung Eun Kim, Mi-Kyung Kim, Moon-Ho Son, Soon Hoe Kim
-
Patent number: 10160724Abstract: The present disclosure relates to a novel tetrahydropyridine derivative compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, methods for preparing the compounds, methods for inhibiting UDP-3-O—(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC), methods for treating Gram-negative bacterial infections, the use of the compounds for the preparation of therapeutic medicaments for treating Gram-negative bacterial infections, and pharmaceutical compositions for prevention or treatment of Gram-negative bacterial infections, which contain the compounds. The compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure can exhibit excellent effects on the treatment bacterial infections.Type: GrantFiled: September 28, 2017Date of Patent: December 25, 2018Assignee: Dong-A St Co., Ltd.Inventors: Sun-Ho Choi, Weon-Bin Im, Sung-Hak Choi, Chong-Hwan Cho, Ho-Sang Moon, Jung-Sang Park, Min-Jung Lee, Hyun-Jung Sung, Jun-Hwan Moon, Seung-Hyun Song, Hyung-Keun Lee, Ji-Hoon Choi, Cheon-Hyoung Park, Yoon-Jung Kim, Jin-Hyuk Kim